Introduction While timely assessment of long‐term survival for patients with colorectal cancer (CRC) is essential for evaluation on early detection and screening programs of colorectal cancer, those data are extremely scarce in China. We aimed to timely and accurately assess long‐term survival for CRC patients in eastern China. Methods Patients diagnosed with CRC during 2004–2018 and followed up until December 31, 2018 from four cancer registries with high‐quality data from Taizhou, eastern China were included. Period analysis was used to calculate 5‐year relative survival (RS) for overall and the stratification by sex, age at diagnosis and region. The projected 5‐year RS of CRC patients during 2019–2023 was also assessed using a model‐based period analysis. Results Overall 5‐year RS for patients with CRC during 2014–2018 reached 78.8%, being 74.9% for men and 86.1% for women. 5‐year RS declined along with aging, decreasing from 84.1% for age < 45 years to 48.9% for age > 74 years, while 5‐year RS for urban area was higher compared to rural area (83.9% vs. 75.8%). Projected overall 5‐year RS of CRC patients could reach 85.9% during the upcoming period 2019–2023. Conclusions We provided, for first time in China using period analysis, most up‐to‐date 5‐year RS for patients with CRC from Taizhou, eastern China and also found 5‐year RS for CRC patients have improved greatly during 2004–2018.
Dear Editor, Regarding the burden of esophageal cancer worldwide in 2020, 604,000 new cases and 544,000 new deaths were estimated according to the latest data on GLOBOCAN. The standardized incidence and mortality of esophageal cancer in China are 2.1 times higher compared to the global average. The 5-year relative survival is an important and comprehensive indicator that reflects the overall effectiveness of cancer screening and treatment. Period analysis is a method providing timely and accurate assessment of 5-year relative survival because it does not need 5-year followup data from cancer registries. 1 While period analysis has widely been used in Western populations, it has rarely been used in China but was for the first time systematically confirmed in China by our group. 2 Therefore, in this study we aimed at providing the latest data on 5-year relative survival for patients with esophageal cancer in Taizhou, Zhejiang province, China, using period analysis.Taizhou City accounts for approximately 10% of the population of Zhejiang Province, China. Actually, we had full access to data from all nine population-based cancer registries from Taizhou City, Zhejiang Province, China. Data on esophageal cancer patients diagnosed during 2004−2018 and followed up till the end of 2018 were retrieved. Regarding the data quality control, we used the criteria that the proportion of death certificate only (DCO) shall be less than 13%, which indicates good quality of cancer registries as recommended by Brenner. 1 Thereby, five cancer registries with DCO cases higher than 13% were excluded after the aforementioned quality control. Eventually we included esophageal cancer patients diagnosed during 2004−2018 from four cancer registries (Luqiao, Yuhuan, Xianju, and Wenling) that demonstrated highquality data. For detailed information on the methodology please refer to the aforementioned paper from our group. 2 In accordance with the International Classification of Diseases, tenth revision (ICD-10), we used the code C15 to classify cases of esophageal cancer. The flow chart of patient selection was shown in Figure 1A. Eventually, over-This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.